Key facts
- It has raised $7.5M; the latest was Early Stage VC ($1.5M) in Jun 2025.
- Notable investors include COMEUP STARS, Digital Healthcare Partners, Intops Investment, K-Startup Center Seattle, Seoul New Technology Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Orange Biomed
- ·The full record, as it builds
Funding rounds
No funding rounds for Orange Biomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orange Biomed
Operator of a biotech company intended to measure the level of glycated hemoglobin. The company specializes in diagnostic offerings, particularly for chronic disease management like diabetes through its portable product, reusable at-home, and delivers lab-accurate results in just a few minutes by using advanced microfluidics and bio-MEMS technology to analyze single blood drops with precision, enabling diabetic patients to get their diabetes diagnosed and prevent complications accessible, affordable, and user-friendly.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 10
- Website
- orangebiomed.com/
- Ownership
- Privately Held (backing)
Orange Biomed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orange Biomed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orange Biomed in its N-PORT filings yet. We sweep new filings monthly.